See What HealthDay Can Do For You
Contact Us

Once-Daily Dose Approved for Prezista

This regimen of anti-HIV drug sanctioned for those with no darunavir resistance

TUESDAY, Dec. 14 (HealthDay News) -- The U.S. Food and Drug Administration has approved a new once-daily dose for Prezista (darunavir), combined with ritonavir to treat people infected with HIV-1.

In a news release, drug maker Tibotec Therapeutics said the approval was meant for adults who hadn't shown resistance to darunavir.

People with chronic liver disease, including hepatitis or cirrhosis, should be carefully monitored while taking Prezista, the company said. They also should be watched for signs of a severe skin reaction, which could include severe rash accompanied by fever, fatigue, muscle or joint pain, or blisters.

Prezista does not "cure" HIV-1 or AIDS, and will not prevent transmitting the infection to others, the drug maker stressed.

More information

To learn more about antiviral drugs used to treat HIV infection, visit the FDA.

Physician's Briefing